Baity Glenn 4
4 · ACADIA PHARMACEUTICALS INC · Filed Sep 1, 2017
Insider Transaction Report
Form 4
Baity Glenn
VP, GC & Sec.
Transactions
- Exercise/Conversion
Common Stock
2017-08-30$1.62/sh+16,507$26,741→ 94,163 total - Sale
Common Stock
2017-08-30$34.87/sh−26,507$924,315→ 67,656 total - Exercise/Conversion
Stock Option (right to buy)
2017-08-30−16,507→ 14,000 totalExercise: $1.62Exp: 2021-03-24→ Common Stock (16,507 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $34.88 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- [F3]25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.